Eli Lilly and Company $LLY is Campbell Newman Asset Management Inc.'s 4th Largest Position

Key Points

• Campbell Newman Asset Management increased its Eli Lilly stake by 71.4% in the second quarter to 53,348 shares worth approximately $63.99 million, making LLY its fourth-largest portfolio position.
• Eli Lilly reported strong quarterly results, with earnings per share of $8.38 versus the $6.40 consensus estimate and revenue of $22.97 billion, up 47.7% year over year.
• Institutional investors own 82.53% of LLY, while insiders have sold 13,500 shares worth roughly $15.96 million over the past 90 days; analysts maintain a broadly positive “Moderate Buy” consensus with a $1,292.18 price target.

Campbell Newman Asset Management Inc. increased its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 71.4% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 53,348 shares of the company's stock after purchasing an additional 22,219 shares during the period. Eli Lilly and Company accounts for about 4.7% of Campbell Newman Asset Management Inc.'s portfolio, making the stock its 4th largest position. Campbell Newman Asset Management Inc.'s holdings in Eli Lilly and Company were worth $63,987,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently bought and sold shares of the company. Field & Main Bank acquired a new position in Eli Lilly and Company during the 2nd quarter valued at approximately $9,426,000. Prosperitas Financial LLC acquired a new stake in shares of Eli Lilly and Company during the second quarter worth $5,659,000. Goodwin Investment Advisory acquired a new stake in shares of Eli Lilly and Company during the second quarter worth $299,000. Lombard Odier Asset Management Europe Ltd purchased a new stake in shares of Eli Lilly and Company during the second quarter valued at $23,148,000. Finally, Archer Investment Corp increased its position in shares of Eli Lilly and Company by 10.6% in the 2nd quarter. Archer Investment Corp now owns 8,262 shares of the company's stock valued at $9,909,000 after acquiring an additional 795 shares during the period. Hedge funds and other institutional investors own 82.53% of the company's stock.

Insider Activity at Eli Lilly and Company

In related news, CAO Donald A. Zakrowski sold 2,000 shares of Eli Lilly and Company stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total transaction of $2,370,020.00. Following the completion of the transaction, the chief accounting officer directly owned 1,526 shares in the company, valued at approximately $1,808,325.26. This trade represents a 56.72% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the company's stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the completion of the sale, the executive vice president owned 11,875 shares in the company, valued at approximately $14,131,250. This represents a 29.63% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 13,500 shares of company stock worth $15,958,170. 0.14% of the stock is owned by corporate insiders.

Eli Lilly and Company Trading Up 0.0%

NYSE LLY opened at $1,160.52 on Thursday. Eli Lilly and Company has a 1 year low of $712.05 and a 1 year high of $1,292.65. The company has a debt-to-equity ratio of 1.41, a current ratio of 1.35 and a quick ratio of 1.00. The company has a market capitalization of $1.09 trillion, a PE ratio of 38.94, a P/E/G ratio of 1.44 and a beta of 0.50. The company has a fifty day moving average of $1,192.23 and a 200 day moving average of $1,068.27.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share for the quarter, topping the consensus estimate of $6.40 by $1.98. The company had revenue of $22.97 billion for the quarter, compared to the consensus estimate of $20.82 billion. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%.The firm's revenue for the quarter was up 47.7% compared to the same quarter last year. During the same period last year, the firm earned $6.31 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Research analysts forecast that Eli Lilly and Company will post 36.35 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be issued a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend is Friday, August 14th. Eli Lilly and Company's dividend payout ratio (DPR) is 23.22%.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Merida acquisition expands Lilly’s pipeline: Lilly agreed to acquire privately held Merida Biosciences for up to $2.875 billion in cash. The deal adds antibody-engineering capabilities and precision therapies targeting autoimmune and allergic diseases, including Phase 1 candidate MER511 for Graves’ disease and thyroid eye disease. Investors may view the transaction as a long-term diversification move that reduces reliance on GLP-1 medicines. Lilly’s Merida Deal Shows the GLP-1 King Is Already Thinking Beyond Obesity
• Positive Sentiment: Zepbound and regulatory developments support the core franchise: A new Zepbound study was presented as potentially favorable for Lilly investors, while a recent FDA action could give Lilly stronger evidence in negotiations with insurers and employers over coverage of certain GLP-1 treatments. These developments may help defend demand as some payers reconsider coverage heading into 2027. Insurers Are Pulling Back From GLP-1 Drugs
• Positive Sentiment: Strong earnings and pipeline optimism remain supportive: Lilly recently reported revenue growth of 47.7% year over year and earnings well above consensus estimates. Analysts and financial commentary continue to highlight the company’s broad pipeline and potential for further growth, with valuation viewed by some investors as attractive relative to its longer-term opportunity. Lilly’s Record Stock Price Is Hiding an Even Bigger Opportunity
• Neutral Sentiment: Near-term uncertainty centers on Merida execution: Merida’s lead drug is still in Phase 1, and much of the purchase price depends on future milestones. The acquisition could create substantial value, but clinical, regulatory and integration risks remain. Lilly is scheduled to participate in the Morgan Stanley Global Healthcare Conference on September 14, which could provide additional strategy or pipeline commentary. Lilly’s $2.88 Billion Immunology Deal Starts in Phase 1

Analyst Upgrades and Downgrades

LLY has been the subject of a number of research reports. Morgan Stanley reaffirmed an "overweight" rating and set a $1,419.00 price target on shares of Eli Lilly and Company in a research report on Thursday, August 6th. Wolfe Research reissued an "outperform" rating and issued a $1,350.00 price objective on shares of Eli Lilly and Company in a report on Thursday, May 21st. Sanford C. Bernstein raised their price objective on Eli Lilly and Company from $1,300.00 to $1,385.00 and gave the stock an "outperform" rating in a research note on Tuesday, July 14th. Cantor Fitzgerald lifted their target price on Eli Lilly and Company from $1,350.00 to $1,410.00 and gave the stock an "overweight" rating in a report on Thursday, August 6th. Finally, Jefferies Financial Group upped their target price on Eli Lilly and Company from $1,330.00 to $1,350.00 and gave the company a "buy" rating in a research report on Tuesday, June 9th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $1,292.18.

Eli Lilly and Company Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source